These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27322425)

  • 1. Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
    Löffler H; Pfarr N; Kriegsmann M; Endris V; Hielscher T; Lohneis P; Folprecht G; Stenzinger A; Dietel M; Weichert W; Krämer A
    Oncotarget; 2016 Jul; 7(28):44322-44329. PubMed ID: 27322425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
    Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
    Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival.
    Visser E; Franken IA; Brosens LAA; de Leng WWJ; Strengman E; Offerhaus JA; Ruurda JP; van Hillegersberg R
    Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
    Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic characterisation of molecular targets in carcinoma of unknown primary.
    Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
    J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
    Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
    Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
    Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
    Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
    Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
    JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).
    Es HA; Mahdizadeh H; Asl AAH; Totonchi M
    Sci Rep; 2021 Jul; 11(1):15112. PubMed ID: 34302033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
    Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
    Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
    Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
    Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.
    Masugi Y; Takamatsu M; Tanaka M; Hara K; Inoue Y; Hamada T; Suzuki T; Arita J; Hirose Y; Kawaguchi Y; Nakai Y; Oba A; Sasahira N; Shimane G; Takeda T; Tateishi K; Uemura S; Fujishiro M; Hasegawa K; Kitago M; Takahashi Y; Ushiku T; Takeuchi K; Sakamoto M;
    J Pathol Clin Res; 2023 Sep; 9(5):339-353. PubMed ID: 37291757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma.
    Barrett MT; Deiotte R; Lenkiewicz E; Malasi S; Holley T; Evers L; Posner RG; Jones T; Han H; Sausen M; Velculescu VE; Drebin J; O'Dwyer P; Jameson G; Ramanathan RK; Von Hoff DD
    Br J Cancer; 2017 Aug; 117(4):572-582. PubMed ID: 28720843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of molecular targets in vulvar cancers.
    Palisoul ML; Mullen MM; Feldman R; Thaker PH
    Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
    Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
    Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.
    Pentheroudakis G; Kotteas EA; Kotoula V; Papadopoulou K; Charalambous E; Cervantes A; Ciuleanu T; Fountzilas G; Pavlidis N
    Clin Exp Metastasis; 2014 Oct; 31(7):761-9. PubMed ID: 24997156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.